Unable To Manage Debts, India’s Wockhardt Calls For Financial Restructuring; Habil Khorakiwala Resigns As Managing Director
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After plunging into a veritable financial crisis due to high debt levels, India's pharmaceutical and biotechnology company Wockhardt has called for a financial debt restructuring through ICICI Bank
You may also be interested in...
India’s Wockhardt Sees Profit Nosedive On The Weight Of Import Bans
Wockhardt earnings reel from mounting regulatory actions from the U.S., UK and EU. Management pledges restructuring to put the company back on track, but no short-term relief is in sight.
Abbott, Wockhardt Terminate Nutritional Business Deal
Pharmaceuticals and diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt call off their $130 million deal for a nutritional business announced less than a year ago
Abbott, Wockhardt Terminate Nutritional Business Deal
Pharmaceuticals and diagnostics giant Abbott and debt-ridden Indian drug maker Wockhardt call off their $130 million deal for a nutritional business announced less than a year ago